|
Match
|
Document |
Document Title |
|
|
US20110064810 |
TISSUE ENGINEERING METHOD FOR ORGAN RECONSTRUCTION USING INJECTABLE MATRIX
The various embodiments herein relate to an injectable matrix used for regeneration, reconstruction, repair or replacement of organ or tissue. The injectable matrix consists of a synthetic and... |
|
|
US20120114754 |
RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient,... |
|
|
US20140294953 |
Abuse-Resistant Formulations
The disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The... |
|
|
US20120282340 |
DRUG DELIVERY SYSTEM
The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain an Estrogen Receptor beta (ER-β) selective agonist. The wafers of the present... |
|
|
US20110293720 |
PROGESTIN-CONTAINING DRUG DELIVERY SYSTEM
The present invention relates to drug delivery compositions in the form of thin water-soluble films (wafers), which contain small particles that comprise at least one progestin and at least one... |
|
|
US20110097405 |
ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM
The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain estradiol, or derivatives thereof, in low amounts. The wafers of the present... |
|
|
US20100316718 |
ACTIVATED FOAM
The present invention relates to an activated foam made of a natural or synthetic rubber or a synthetic resin, characterized in that the foam contains a zirconium compound and/or a germanium... |
|
|
US20110117196 |
Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
The invention provides a novel solid pharmaceutical dosage form which includes an opiate, an opiate antagonist admixed with the analgetic (opiate agonist) and an amount of a hydrocolloid... |
|
|
US20130039981 |
Quick Dissolving, Long Acting Zinc Therapeutic Formulations
The present invention comprises a quick dissolving, long acting zinc therapeutic cold formulation containing high levels of an active compound encapsulated within bioadhesive/muco-adhesive... |
|
|
US20130171256 |
ALCOHOL-RESISTANT EXTENDED RELEASE DOSAGE FORMS COMPRISING VENLAFAXINE
This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing venlafaxine or a pharmaceutically... |
|
|
US20110104273 |
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF PHENYLEPHRINE
Gastric retentive dosage forms for both immediate and extended release of phenylephrine are described which allow once- or twice-daily dosing. Methods of treatment using the dosage forms and... |
|
|
US20110027361 |
EXTENDED RELEASE DOSAGE FORM OF PALIPERIDONE
The present invention relates to an extended release solid oral pharmaceutical composition comprising Paliperidone or its pharmaceutically acceptable salts and process for preparing the same. |
|
|
US20100151028 |
CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one... |
|
|
US20120207836 |
DRUG DELIVERY SYSTEMS (WAFER) FOR PEDIATRIC USE
The present invention describes drug delivery compositions in the form of thin water-soluble films (wafers), which contain particles that comprise at least one active ingredient—which is not an... |
|
|
US20110244045 |
CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION
The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present... |
|
|
US20130071476 |
Rapid Melt Controlled Release Taste-Masked Compositions
Rapid melt tablets that dissolve and release an active component in the oral cavity are comprised of a pharmaceutical active ingredient such as dextromethorphan complexed with a resin that is... |
|
|
US20050118269 |
External preparation for wounds
There is provided an external preparation for wounds which has novel usability in treating skin damages accompanied by a large amount of exudation such as bedsores, skin ulcers, and burns, and yet... |
|
|
US20120201891 |
TRANSDERMAL DELIVERY PATCH
A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer... |
|
|
US20120130300 |
Therapeutic Methods Using Controlled Delivery Devices Having Zero Order Kinetics
An injectable or implantable medical device having orifice(s) on the surface that release an active agent with zero-order release kinetics is described herein. The device is a hollow matrix of any... |
|
|
US20110052699 |
DRUG DELIVERY SYSTEM WITH STABILISING EFFECT
A drug delivery system also intended as unit dosage form comprising a thin water-soluble film matrix, wherein said film matrix comprises a) a polyvinyl alcohol-polyethylene glycol graft copolymer... |
|
|
US20090022780 |
HYDROGEL
The invention is related to gel preparations capable of absorbing as well as releasing liquid, and the use of such gel preparations in the treatment of wounds. |
|
|
US20150209412 |
INSULIN-CONTAINING INFANT FORMULA
The present invention provides compositions methods and kits for improved infant formula, particularly to insulin-supplements and formulae comprising same that mimic the diurnal rhythm and/or the... |
|
|
US20080146109 |
LAMINATES OF ACID POLYSACCHARIDE FILMS
The present invention relates to a laminate prepared in part from a continuous acid polysaccharide film. In various embodiments, the laminate is useful for fabrication as a protective article as... |
|
|
US20120288566 |
LIQUID PRECURSOR COMPOSITIONS AND USES THEREOF FOR A PH-DEPENDANT SUSTAINED RELEASE TREATMENT OF ORAL DISORDERS
The present invention discloses liquid precursor compositions adapted for application on a hard surface in the oral cavity, comprising at least one therapeutic agent suitable for the treatment of... |
|
|
US20100291245 |
SOFT, CHEWABLE AND ORALLY DISSOLVABLE AND/OR DISINTEGRABLE PRODUCTS
A soft, chewable and orally dissolvable and/or disintegrable product includes a biopolymer-sugar based matrix and botanical powder dispersed throughout the biopolymer-sugar based matrix. The... |
|
|
US20110150993 |
Fine Particle Croscarmellose and Uses Thereof
The disclosure is directed to fine particle croscarmellose and its use in various compositions such as solid dosage forms. More specifically, the present disclosure relates to fine particle... |
|
|
US20100285125 |
DELIVERY SYSTEM FOR POORLY SOLUBLE DRUGS
The present invention relates to an oral drug delivery system for poorly soluble drugs, which can provide sustained near zero order release of poorly water soluble drugs from erodible matrix... |
|
|
US20050287215 |
Hemostatic compositions and devices
The present inventions includes a plurality of packed particles that contain interstitial pores, where the interstitial pores have a pore volume and a median pore diameter effective to provide... |
|
|
US20090324714 |
DUAL ADHESIVE TECHNOLOGY
A dual adhesive layer dosage form for delivery of active agent to and across, the mucosa is disclosed. Particularly, bioadhesive tablets for administration at the vaginal mucosa are disclosed as... |
|
|
US20090053307 |
IMMEDIATE-RELEASE THERAPEUTIC SYSTEMS FOR IMPROVED ORAL ABSORPTION OF 7-[(E)]-T-BUTY-LOXYMINOMETHYL] CAMPTOTHECIN
A pharmaceutical composition comprising a camptothecin as active ingredient is herein described. In particular immediate-release therapeutic systems are described for the improved oral absorption... |
|
|
US20100074955 |
Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity
The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least NMDA-receptor ligand, a medicament comprising said... |
|
|
US20110217378 |
IMMOBILIZATION OF BIOACTIVE MOLECULES WITHIN A POLYMERIC SUBSTRATE
It is described a technology which allows to surpass the gastric barrier for proteic compounds administrating bioactive molecules, particularly insulin. It is proposed a method to replace the... |
|
|
US20120183618 |
MODULAR SYSTEMS FOR THE CONTROLLED RELEASE OF A SUBSTANCE WITH SPACE AND TIME CONTROL
An innovative pharmaceutical form for controlled drug release relates to systems obtained by the assembly of individual release modules, of which the capacity to release the drug in time and in... |
|
|
US20120183609 |
MODULAR SYSTEMS FOR THE CONTROLLED RELEASE OF A SUBSTANCE WITH SPACE AND TIME CONTROL
An innovative pharmaceutical form for controlled drug release relates to systems obtained by the assembly of individual release modules, of which the capacity to release the drug in time and in... |
|
|
US20090017120 |
Phase stable lecithin organogel composition
A lecithin organogel composition used to deliver pharmaceutical products transdermally as well as a method for producing the lecithin organogel composition, which may contain up to 40% additive... |
|
|
US20070292515 |
Solid dosage form containing a taste masked active agent
A solid dosage form containing a taste masked active agent is provided. The solid dosage form may be provided as a water soluble film that is disintegrable in the oral cavity to deliver and... |
|
|
US20080050434 |
Novel Composition for Topical Delivery
Pharmaceutical composition for topical administration comprising of at least one active ingredient, its salts, esters, hydrates or derivatives; a gelator system consisting of a fiend of... |
|
|
US20090297597 |
Modified Release Ticlopidine Compositions
The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers ticlopidine in a bimodal, multimodal or continuous manner. The... |
|
|
US20080220064 |
EXTENDED RELEASE MATRIX FORMULATIONS OF MORPHINE
The present invention provides extended-release matrix formulations comprising a therapeutically effective amount of morphine or salt thereof, one or more hydrophilic controlled release polymers... |
|
|
US20070254034 |
Activated Foam
The present invention relates to an activated foam made of a natural or synthetic rubber or a synthetic resin, characterized in that the foam contains a zirconium compound and/or a germanium... |
|
|
US20100291179 |
COMPOSITE BIOMATERIAL FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS
The present invention relates to a composite biomaterial and a process for producing a composite biomaterial with controlled release of active ingredients, comprising a three-dimensional... |
|
|
US20120247993 |
Probiotic Compositions, Methods and Apparatus for Their Administration
A probiotic composition including a probiotic microorganism embedded within a matrix, the matrix substantially maintaining the viability of said microorganisms. The matrix releases said... |
|
|
US20080095848 |
Pharmaceutical Composition For Topical Use In Form Of Xerogels Or Films And Methods For Production
The present invention relates to dry delivery system comprising a xerogel or film with applied active ingredients for topical active ingredient delivery or other purposes. Said delivery system are... |
|
|
US20100151013 |
Gastric acid secretion inhibiting composition
An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on... |
|
|
US20100215724 |
Microcapsule Nanotube Devices for Targeted Delivery of Therapeutic Molecules
A nanotube device comprises a gel matrix that includes microcapsules and functionalized nanotubes, or other functionalized nanostructures incorporated into said gel matrix. Pharmaceutical... |
|
|
US20090214604 |
Method of obtaining hydrogels of cyclodextrins with glycidyl ethers, compositions thus obtained and applications thereof
The invention relates to a method of obtaining hydrogels based on (i) cyclodextrins, (ii) cyclodextrins and cellulose ethers or (iii) cyclodextrins and guar gum or the derivatives of same, using... |
|
|
US20100183688 |
Delivery System and Method of Manufacturing the Same
A microparticle delivery system for an active compound which includes an active compound loaded onto polymeric microparticles, wherein the loaded microparticles are encased by a matrix material... |
|
|
US20080095847 |
STIMULUS-RELEASE CARRIER, METHODS OF MANUFACTURE AND METHODS OF TREATMENT
Compositions, methods of fabrication and methods of treatment for the controlled release of a therapeutic substance to a treatment region are disclosed herein. In some embodiments, block... |
|
|
US20080206334 |
Pharmaceutical Polymer Composition For Oral Controlled-Release Delivery Of Terbutaline Sulfate
The present invention is directed to a controlled-release pharmaceutical composition providing a sustained delivery of the basic drug Terbutaline sulfate, said composition comprising at least... |
|
|
US20100260835 |
PHARMACEUTICAL COMPOSITION
A pharmaceutical composition comprising a moulded body of a polymer matrix, said polymer matrix comprising at least one polyaphron dispersion and at least one pharmaceutically active agent... |